AR034216A1 - Metodo de extraccion de virus a partir de cultivos celulares y composiciones que comprenden dicho virus - Google Patents
Metodo de extraccion de virus a partir de cultivos celulares y composiciones que comprenden dicho virusInfo
- Publication number
- AR034216A1 AR034216A1 ARP020100923A ARP020100923A AR034216A1 AR 034216 A1 AR034216 A1 AR 034216A1 AR P020100923 A ARP020100923 A AR P020100923A AR P020100923 A ARP020100923 A AR P020100923A AR 034216 A1 AR034216 A1 AR 034216A1
- Authority
- AR
- Argentina
- Prior art keywords
- virus
- detergent
- reovirus
- compositions
- minutes
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 12
- 238000004113 cell culture Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000000605 extraction Methods 0.000 title 1
- 239000003599 detergent Substances 0.000 abstract 6
- 241000702263 Reovirus sp. Species 0.000 abstract 4
- 241000702244 Orthoreovirus Species 0.000 abstract 2
- 239000013504 Triton X-100 Substances 0.000 abstract 2
- 229920004890 Triton X-100 Polymers 0.000 abstract 2
- 238000011534 incubation Methods 0.000 abstract 2
- 229920001213 Polysorbate 20 Polymers 0.000 abstract 1
- 229960003964 deoxycholic acid Drugs 0.000 abstract 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 abstract 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 abstract 1
- 230000000384 rearing effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/765—Reovirus; Rotavirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12251—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Un método para producir virus a partir de un cultivo de células, que comprende los pasos de: (a) proveer un cultivo de células que ha sido infectado por el virus; (b) extraer el virus de las células por adición de un detergente al cultivo e incubación por un período de tiempo; y (c) recolectar el virus. Se pueden extraer virus infecciosos del cultivo con un detergente a una temperatura conveniente, tal como 25°C ó 37°C, para obtener títulos virales altos. Se pueden usar detergentes no iónicos y iónicos. Particularmente, el detergente se selecciona del grupo formado por Tritón X-100, Tween 20, NP-40 y deoxicolato de sodio. Se prefiere que el detergente sea Tritón X-100, en particular a una concentración final del 1%. El cultivo celular se incuba con el detergente en un período de tiempo suficiente como para provocar la ruptura de las células. El período de incubación es preferentemente de 60 minutos o menos, más preferentemente de 30 minutos o menos y más preferentemente aún de 10 minutos. En una realización preferida el virus es un virus sin envoltura. El virus sin envoltura es preferentemente un reovirus, particularmente un reovirus mamífero. Los reovirus de mamíferos son preferentemente reovirus humanos, más preferentemente el serotipo 3 de reovirus y con mayor preferencia el reovirus de la cepa Dearing. Se describen composiciones que comprenden el virus recolectado, en particular composiciones adecuadas para la administración clínica. Preferiblemente el virus es reovirus. Las composiciones pueden también comprender un excipiente y/o vehículo aceptable para uso farmacéutico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27673401P | 2001-03-16 | 2001-03-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR034216A1 true AR034216A1 (es) | 2004-02-04 |
Family
ID=29420186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020100923A AR034216A1 (es) | 2001-03-16 | 2002-03-14 | Metodo de extraccion de virus a partir de cultivos celulares y composiciones que comprenden dicho virus |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6808916B2 (es) |
| EP (2) | EP1370643A1 (es) |
| JP (2) | JP4087712B2 (es) |
| AR (1) | AR034216A1 (es) |
| BR (1) | BR0207527A (es) |
| CA (1) | CA2437962C (es) |
| DK (1) | DK2253701T3 (es) |
| ES (1) | ES2500645T3 (es) |
| IL (2) | IL157304A0 (es) |
| MX (1) | MXPA03007535A (es) |
| NZ (1) | NZ527525A (es) |
| WO (1) | WO2002074940A1 (es) |
| ZA (1) | ZA200306228B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1501921T4 (da) | 2002-04-30 | 2012-10-08 | Oncolytics Biotech Inc | Forbedrede virusrensningsmetoder |
| JP4389870B2 (ja) * | 2003-06-10 | 2009-12-24 | 株式会社島津製作所 | 哺乳動物培養細胞抽出液を用いた無細胞系タンパク質合成方法 |
| US7901921B2 (en) * | 2004-10-22 | 2011-03-08 | Oncolytics Biotech Inc. | Viral purification methods |
| US10668119B2 (en) | 2005-08-01 | 2020-06-02 | Virocure, Inc. | Attenuated reovirus |
| EP1917351A4 (en) | 2005-08-01 | 2009-12-16 | Univ Technologies Int | WEAKEN REOVIRUS |
| CA2678721C (en) | 2007-03-12 | 2018-02-13 | Oncolytics Biotech Inc. | Reoviruses having modified sequences |
| US10369171B2 (en) | 2007-03-13 | 2019-08-06 | Virocure, Inc. | Attenuated reoviruses for selection of cell populations |
| AR066649A1 (es) * | 2007-05-21 | 2009-09-02 | Oncolytics Biotech Inc | Reovirus mutantes y metodos de elaboracion y uso de los mismos |
| MX2010003556A (es) * | 2007-10-22 | 2010-04-21 | Oncolytics Biotech Inc | Regimen de tratamiento para trastornos proliferantes. |
| CN201163385Y (zh) * | 2008-01-15 | 2008-12-10 | 昆山渝榕电子有限公司 | 笔记本电脑及其脚垫 |
| WO2009143611A1 (en) * | 2008-05-27 | 2009-12-03 | Oncolytics Biotech Inc. | Abrogating proinflammatory cytokine production during oncolytic reovirus therapy |
| US20110086005A1 (en) * | 2008-05-27 | 2011-04-14 | Oncolytics Biotech Inc. | Modulating interstitial pressure and oncolytic viral delivery and distribution |
| CA2819246C (en) | 2010-12-02 | 2023-04-25 | Oncolytics Biotech Inc. | Liquid viral formulations |
| US9044498B2 (en) | 2010-12-02 | 2015-06-02 | Oncolytics Biotech Inc. | Lyophilized viral formulations |
| ES2822199T3 (es) | 2011-04-29 | 2021-04-29 | Oncolytics Biotech Inc | Métodos de purificación de virus usando cromatografía por permeación en gel |
| WO2014152524A2 (en) * | 2013-03-15 | 2014-09-25 | Ansun Biopharma, Inc. | Novel method of protein purification |
| ES2796950T3 (es) | 2013-11-15 | 2020-11-30 | Oncolytics Biotech Inc | Virus oncolíticos y regímenes reforzados para tratamiento de cáncer |
| US10280199B2 (en) | 2014-02-07 | 2019-05-07 | Phibro Animal Health Corporation | Coronavirus proteins and antigens |
| WO2016130569A1 (en) * | 2015-02-09 | 2016-08-18 | Mj Biologics, Inc. | A composition comprising pedv antigens and methods for making and using the composition |
| EP3172317B1 (en) | 2014-07-24 | 2019-05-01 | Janssen Vaccines & Prevention B.V. | Process for the purification of poliovirus from cell cultures |
| GB201417042D0 (en) | 2014-09-29 | 2014-11-12 | Fkd Therapies Oy | Method |
| WO2019086463A1 (en) | 2017-10-30 | 2019-05-09 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| US12460270B2 (en) | 2018-02-28 | 2025-11-04 | Regeneron Pharmaceuticals, Inc. | Systems and methods for identifying viral contaminants |
| WO2023277173A1 (ja) * | 2021-06-30 | 2023-01-05 | 旭化成メディカル株式会社 | ウイルスの回収方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| JPS6344532A (ja) | 1986-08-11 | 1988-02-25 | Biseibutsu Kagaku Kenkyusho:Kk | 豚のレオウイルス感染症ワクチン |
| US5614413A (en) * | 1993-07-01 | 1997-03-25 | The Uab Research Foundation | Encapsidated recombinant poliovirus nucleic acid and methods of making and using same |
| HRP950097A2 (en) * | 1994-03-08 | 1997-06-30 | Merck & Co Inc | Hepatitis a virus culture process |
| US6146873A (en) * | 1994-11-10 | 2000-11-14 | Baxter Aktiengesellschaft | Production of orthomyxoviruses in monkey kidney cells using protein-free media |
| JP4492826B2 (ja) * | 1996-11-20 | 2010-06-30 | イントロジェン セラピューティクス，インコーポレイテッド | アデノウイルスベクターの産生および精製のための改良された方法 |
| US6214333B1 (en) * | 1997-07-08 | 2001-04-10 | Texas Heart Institute | Vasoprotective recombinant adenovirus vector containing a human TFPI gene |
| US6110461A (en) | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
| TWI289158B (en) * | 2000-08-10 | 2007-11-01 | Oncolytics Biotech Inc | Method of producing infectious reovirus |
-
2002
- 2002-03-11 EP EP02708064A patent/EP1370643A1/en not_active Withdrawn
- 2002-03-11 ES ES10171853.4T patent/ES2500645T3/es not_active Expired - Lifetime
- 2002-03-11 MX MXPA03007535A patent/MXPA03007535A/es active IP Right Grant
- 2002-03-11 WO PCT/CA2002/000331 patent/WO2002074940A1/en not_active Ceased
- 2002-03-11 CA CA002437962A patent/CA2437962C/en not_active Expired - Lifetime
- 2002-03-11 EP EP10171853.4A patent/EP2253701B1/en not_active Expired - Lifetime
- 2002-03-11 BR BR0207527-0A patent/BR0207527A/pt not_active IP Right Cessation
- 2002-03-11 JP JP2002574332A patent/JP4087712B2/ja not_active Expired - Lifetime
- 2002-03-11 IL IL15730402A patent/IL157304A0/xx unknown
- 2002-03-11 NZ NZ527525A patent/NZ527525A/en unknown
- 2002-03-11 DK DK10171853.4T patent/DK2253701T3/da active
- 2002-03-14 US US10/097,183 patent/US6808916B2/en not_active Expired - Lifetime
- 2002-03-14 AR ARP020100923A patent/AR034216A1/es unknown
-
2003
- 2003-08-07 IL IL157304A patent/IL157304A/en active IP Right Grant
- 2003-08-12 ZA ZA200306228A patent/ZA200306228B/en unknown
-
2004
- 2004-08-10 US US10/916,378 patent/US7186542B2/en not_active Expired - Lifetime
-
2007
- 2007-08-15 JP JP2007211995A patent/JP2007295937A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1370643A1 (en) | 2003-12-17 |
| IL157304A (en) | 2010-04-29 |
| EP2253701A1 (en) | 2010-11-24 |
| JP2007295937A (ja) | 2007-11-15 |
| US6808916B2 (en) | 2004-10-26 |
| DK2253701T3 (da) | 2014-10-20 |
| CA2437962A1 (en) | 2002-09-26 |
| US7186542B2 (en) | 2007-03-06 |
| ES2500645T3 (es) | 2014-09-30 |
| WO2002074940A1 (en) | 2002-09-26 |
| NZ527525A (en) | 2005-03-24 |
| US20020168764A1 (en) | 2002-11-14 |
| CA2437962C (en) | 2005-11-15 |
| MXPA03007535A (es) | 2003-12-11 |
| US20050095692A1 (en) | 2005-05-05 |
| BR0207527A (pt) | 2004-02-25 |
| HK1150859A1 (en) | 2012-01-13 |
| JP2004520841A (ja) | 2004-07-15 |
| IL157304A0 (en) | 2004-02-19 |
| ZA200306228B (en) | 2004-08-12 |
| JP4087712B2 (ja) | 2008-05-21 |
| EP2253701B1 (en) | 2014-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR034216A1 (es) | Metodo de extraccion de virus a partir de cultivos celulares y composiciones que comprenden dicho virus | |
| Weaver et al. | Population bottlenecks and founder effects: implications for mosquito-borne arboviral emergence | |
| Weger-Lucarelli et al. | Vector competence of American mosquitoes for three strains of Zika virus | |
| Haddow et al. | High infection rates for adult macaques after intravaginal or intrarectal inoculation with Zika virus | |
| McLean et al. | A novel insect-specific flavivirus replicates only in Aedes-derived cells and persists at high prevalence in wild Aedes vigilax populations in Sydney, Australia | |
| AR039783A1 (es) | Metodos mejorados de purificacion viral | |
| AR033993A1 (es) | Metodo para producir reovirus infeccioso y de mamifero, y composicion de reovirus | |
| ES2139553T1 (es) | Replicacion de virus de la gripe en un cultivo de celulas de mamiferos y produccion de vacuna. | |
| Tian et al. | Protective efficacy of the H5 inactivated vaccine against different highly pathogenic H5N1 avian influenza viruses isolated in China and Vietnam | |
| ES2421543T3 (es) | Método para la preparación de virus y proteínas del PRRS, y kits de pruebas de diagnóstico para su detección | |
| Ng et al. | Topographic changes in SARS coronavirus–infected cells at late stages of infection | |
| CN101372682A (zh) | 褐点石斑鱼鳍细胞系的构建方法 | |
| Koptopoulos et al. | The epizootology of caprine herpesvirus (BHV-6) infections in goat populations in Greece | |
| Vestergárd Jørgensen | Indirect fluorescent antibody techniques for demonstration of trout viruses and corresponding antibody | |
| Planzer et al. | In vivo and in vitro propagation and transmission of Toggenburg orbivirus | |
| Griffin et al. | Demonstration of virus particles in biopsy material from cases of Burkitt's tumour | |
| CN102242173B (zh) | 一种石斑鱼虹彩病毒囊膜蛋白的提取方法 | |
| Jadi et al. | Chandipura virus growth kinetics in vertebrate cell lines, insect cell lines & embryonated eggs | |
| CN101451121B (zh) | 褐点石斑鱼心脏细胞系的构建方法 | |
| Barreto‐Vieira et al. | MPXV: update on morphological and morphogenesis aspects through transmission and scanning electron microscopies and 3D reconstruction | |
| Skern | 100 years poliovirus: from discovery to eradication. A meeting report | |
| Koski | A RHABDOVIRUS ISOLATED FROM BROWN TROUT (SALMO TRUTTA m. LACUSTRIS (L.)) WITH LESIONS IN PARENCHYMATOUSn | |
| CN105462931A (zh) | 一种猪肠道上皮细胞系及其应用 | |
| CN107854499B (zh) | 诃子在制备抑制和杀灭牛病毒性腹泻病毒bvdv药物中的应用 | |
| Fang et al. | Investigating the virulence of coxsackievirus B6 strains and antiviral treatments in a neonatal murine model |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |